BMS to Build State-of-the-Art Campus in Lawrenceville, NJ
Bristol-Myers Squibb Company (BMS) has announced plans to build a 650,000-sq ft office building on company-owned land at the intersection of Princeton Pike and Interstate 295 in Lawrenceville, New Jersey. Construction is expected to begin this fall and the new facility is expected to open by the end of 2016.
The new facility is part of the company’s broader strategic plan to modernise its workspace to enable greater collaboration, increase technological capabilities and enhance productivity. The new facility will allow the company to consolidate operations currently located in leased office space at 777 Scudders Mill Road in Plainsboro Township and at Nassau Park Boulevard in West Windsor Township. The Princeton Pike location was purchased by BMS from RCN Corp. in 2001.
“We are proud to expand our presence in Lawrenceville, a community that has been home to our company for more than 40 years,” says CEO Lamberto Andreotti. “Our new campus will create a dynamic and modern workplace to advance the important work that our employees are doing to discover, develop and deliver innovative medicines for patients with serious diseases.”
The Lawrence Township Planning Board unanimously approved final site plans for the new campus in June. The new campus will be the company’s second in Lawrence Township, joining its worldwide headquarters at US Route 206 and Province Line Road, which opened in 1971. The company currently employs more than 2000 people at the Route 206 campus and more than 6000 in Central New Jersey. Once completed, as many as 2500 people will work at the new facility.
“I'm excited that BMS has decided to increase their investment in Lawrence Township,” says Lawrence Township Mayor Cathleen Lewis. “The company has been a constant partner in making Lawrence Township a great community; this new project will continue that legacy. We appreciate the confidence BMS has shown in our town and it is another sign that Lawrence is a great place for businesses to invest.”
The new facility represents the company’s broader strategic initiative to modernise its facilities through improved technology, more efficient design and workspace that enables collaboration, creativity and innovation. Employees will have state-of-the-art tools to collaborate and enhance their productivity, including personal desktop video capabilities and an immersive, high-definition video conferencing environment. The entire working environment will be both wired and wireless to enable employees to access the applications and information they need no matter where they are on the campus while using whatever computing device makes them most productive. BMS is introducing similar open work spaces around the world.
The new campus also is designed to be friendly to the environment and neighbors. The buildings are targeted to meet LEED certification standards for energy and environmental design. Most mechanical equipment will be located below ground to reduce noise. The site plans preserve the historic Brearley Oak tree located directly opposite Lenox Drive. A segment of the Lawrence Hopewell Trail on the campus will link to a network of walking paths on the property, and nearly half of the 134-acre tract will remain working farmland. There will be preferred parking areas for hybrid vehicles and indoor bicycle racks. The parking areas will be paved with porous pavement to reduce runoff and promote recharging of groundwater aquifers.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.